| Name | Title | Contact Details |
|---|
OM1 is a leading health outcomes and registries company focused on the measurement, comparison, and prediction of treatment outcomes. Leveraging big data, standardized outcomes measurement, and artificial intelligence technology, OM1 built the first intelligent data cloud for healthcare, enabling more precise information and better decision making for stakeholders across the healthcare ecosystem.
St. Paul County Family and Community Support Services is a St Paul, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Shore Medical Center operates as a hospital facility. It offers anesthesiology, balance, blood bank, cancer, cardiovascular, critical, diabetes education, endoscopy, hospitalist, kidney disease, laboratory, maternal-fetal medicine, neurosciences, nutrition, outpatient testing, palliative, pulmonary diagnostic, radiology and diagnostic imaging, rehabilitation, respiratory, sleep medicine, social, spine and orthopedic, stroke, surgical, urgent, wound and hyperbaric medicine, vascular, neurological, emergency, and maternity and pediatric health care services. Shore Medical Center was formerly known as Shore Medical Center. The company is based in Somers Point, New Jersey. Shore Medical Center operates as a subsidiary of Shore Health Systems Inc.
North Coast Health Ministry is a Lakewood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.